EIF2AK2

Across TCGA pan-cancer cohorts, EIF2AK2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated EIF2AK2 data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher EIF2AK2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated EIF2AK2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where EIF2AK2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.415	0.897	<.001	15	view →
CCRCC	DFS	Tertile	III,IV	0.496	0.807	.023	8	view →
LUAD	OS	Tertile	II,III,IV	1.000	0.825	.027	8	view →
LSCC	DFS	Tertile	All	0.927	0.356	.016	6	view →
UCEC	DFS	Tertile	All	0.839	0.973	.044	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

EIF2AK2–PDAC (DFS)

Open the PDAC breakdown →